Santella R M, Nunes M G, Blaskovic R, Perera F P, Tang D, Beachman A, Lin J H, DeLeo V A
Cancer Center/Division of Environmental Science, School of Public Health, Columbia University, New York, New York 10032.
Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):137-40.
Coal tar-treated psoriasis patients were used as a model population to test a newly developed enzyme-linked immunosorbent assay (ELISA) for urinary excretion of benzo(a)pyrene and related polycyclic aromatic hydrocarbons (PAHs). The ability of the ELISA to detect exposure was also compared with that of two previously established biomonitoring methods, measurement of urinary 1-hydroxypyrene by high performance liquid chromatography with fluorescence detection and mutagenicity measured by the Salmonella typhimurium mutagenesis assay. Urine samples were collected from 57 patients and 53 untreated volunteers. Urinary excretion of PAH metabolites, measured by competitive ELISA with a monoclonal antibody (4D5), was elevated in patients (mean, 730 +/- 1370 mumol/mol creatinine) compared with untreated volunteers (110 +/- 90 mumol/mol creatinine; P < 0.0001). 1-Hydroxypyrene also was elevated in patients (mean, 547 +/- 928 mumol/mol creatinine) compared with volunteers (mean, 0.14 +/- 0.17 mumol/mol creatinine; P < 0.0001). Much larger differences between mean values in patients and volunteers were observed with the 1-hydroxypyrene assay compared with the PAH metabolite ELISA. No significant effect of smoking could be detected by either assay. Analysis by the Salmonella typhimurium mutagenesis assay indicated elevated mutagenicity in urine from patients (1410 +/- 2750 revertants/mmol creatinine) compared with volunteers (715 +/- 846 revertants/mmol creatinine; P = 0.072). In all subjects, there was a good correlation between the PAH metabolites and both 1-hydroxypyrene (r = 0.717; P < 0.0001) and urinary mutagenicity (r = 0.317; P = 0.004). These results suggest that the ELISA, which easily can be carried out on large numbers of samples, can be used for monitoring urinary excretion of PAHs in a high exposure population. Ongoing studies are designed to determine its applicability to lower exposure populations.
以煤焦油治疗的银屑病患者作为模型人群，来测试一种新开发的用于检测尿中苯并(a)芘及相关多环芳烃(PAHs)排泄的酶联免疫吸附测定(ELISA)。还将ELISA检测暴露的能力与两种先前建立的生物监测方法进行了比较，即通过高效液相色谱荧光检测法测量尿中1-羟基芘，以及通过鼠伤寒沙门氏菌诱变试验测量致突变性。从57例患者和53名未治疗的志愿者中收集尿样。与未治疗的志愿者(110±90μmol/mol肌酐)相比，患者中通过与单克隆抗体(4D5)竞争ELISA法测得的PAH代谢物尿排泄量升高(均值为730±1370μmol/mol肌酐；P<0.0001)。与志愿者(均值为0.14±0.17μmol/mol肌酐；P<0.0001)相比患者中1-羟基芘也升高(均值为547±928μmol/mol肌酐)。与PAH代谢物ELISA相比，1-羟基芘测定在患者和志愿者的均值之间观察到更大的差异。两种检测方法均未检测到吸烟的显著影响。通过鼠伤寒沙门氏菌诱变试验分析表明，与志愿者(715±846回复突变体/mmol肌酐；P = 0.072)相比，患者尿液中的致突变性升高(1410±2750回复突变体/mmol肌酐)。在所有受试者中，PAH代谢物与1-羟基芘(r = 0.717；P<0.0001)和尿致突变性(r = 0.317；P = 0.004)之间均存在良好的相关性。这些结果表明，ELISA易于对大量样品进行检测，可用于监测高暴露人群中PAHs的尿排泄。正在进行的研究旨在确定其对低暴露人群的适用性。
